Applicant, as named in the Orange Book

Tris Pharma Inc

Next listed expiry: Dyanavel Xr on 7 Sep 2036. 6 products with live protection, 0 without.

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis
Dyanavel Xr amphetamine; amphetamine aspartate/dextroamphetamine sulfate	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	208147	7 Sep 2036	patent
Dyanavel Xr 10 amphetamine; amphetamine aspartate/dextroamphetamine sulfate	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	210526	11 Feb 2040	patent, carve-out possible
Dyanavel Xr 15 amphetamine; amphetamine aspartate/dextroamphetamine sulfate	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	210526	11 Feb 2040	patent, carve-out possible
Dyanavel Xr 20 amphetamine; amphetamine aspartate/dextroamphetamine sulfate	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	210526	11 Feb 2040	patent, carve-out possible
Dyanavel Xr 5 amphetamine; amphetamine aspartate/dextroamphetamine sulfate	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	210526	11 Feb 2040	patent, carve-out possible
Onyda Xr clonidine hydrochloride	clonidine hydrochloride	217645	28 Jul 2041	patent

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.